Zealand Pharma ASZLDPF -2.85%62 3-Year ROIIC % is 2,216.41 as of Dec. 2025, which is 806% above its 10-year median of 244.58. GuruFocus rates ZLDPF with a GF Score™ of 62/100 and a GF Value™ of $2,423.11 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,320 Biotechnology companies, Zealand Pharma AS ranks better than 97.05% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Zealand Pharma AS's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 2,216.41%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Zealand Pharma AS's 3-Year ROIIC % or its related term are showing as below:
ZLDPF's 3-Year ROIIC % is ranked better than 97.05% of 1320
companies
in the Biotechnology industry
Industry Median: -4.42
vs ZLDPF: 2216.41
Zealand Pharma AS (OTCPK:ZLDPF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Zealand Pharma AS 3-Year ROIIC % Related Terms
Zealand Pharma AS 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZLDPF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Zealand Pharma AS's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Zealand Pharma AS (ZLDPF) has a 3-Year ROIIC % of 2,216.41 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Zealand Pharma AS and its competitors. This is 806% above median its historical median of 244.58. According to the industry distribution chart, Zealand Pharma AS ranks #39 out of 1320 companies in the Biotechnology industry, placing it in the top 3%.
Is Zealand Pharma AS's 3-Year ROIIC % too high?
Zealand Pharma AS's current 3-Year ROIIC % of 2,216.41 is 806% above median its 10-year median of 244.58. Based on the distribution chart, Zealand Pharma AS ranks #39 out of 1320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #39 out of 1320 companies for 3-Year ROIIC %. This places Zealand Pharma AS in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Zealand Pharma AS and its competitors. Zealand Pharma AS's current 3-Year ROIIC % is 2,216.41, which is 806% above median its own 10-year median of 244.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $2,423.11, compared to a current price of $45.61 — trading 98.1% below its estimated fair value. The current 3-Year ROIIC % is 2,216.41, which is 806% above median its 10-year median of 244.58. Zealand Pharma AS's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current 3-Year ROIIC % is 2,216.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of $45.61 is trading 98.1% below its estimated GF Value™ of $2,423.11.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for ZLDPF:
3-Year ROIIC %: 2,216.41 (806% above median its 10-year median of 244.58)
GF Value™: $2,423.11 vs. price of $45.61 (98.1% below fair value)
No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score
Get the complete analysis for ZLDPF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
